Bellerophon Therapeutics Inc
NASDAQ:BLPH
Bellerophon Therapeutics Inc
NASDAQ:BLPH
Price:
0.0625 USD
21.83%
Updated:
May 3, 2024
Bellerophon Therapeutics Inc
Operating Income
|
Bellerophon Therapeutics Inc
Operating Income Peer Comparison
Comparables:
BDX
BSX
SYK
ABT
ISRG
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bellerophon Therapeutics Inc
NASDAQ:BLPH
|
Operating Income
-$14m
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Operating Income
$2.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Operating Income
$2.5B
|
CAGR 3-Years
46%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Stryker Corp
NYSE:SYK
|
Operating Income
$4.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Operating Income
$6.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Operating Income
$1.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
See Also
What is Bellerophon Therapeutics Inc's Operating Income?
Operating Income
-14m
USD
-14m
USD
Based on the financial report for Jun 30, 2023, Bellerophon Therapeutics Inc's Operating Income amounts to -14m USD.
What is Bellerophon Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
14%
14%
Over the last year, the Operating Income growth was 34%. The average annual Operating Income growth rates for Bellerophon Therapeutics Inc have been 9% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
